

also revealed negative regulation of gene sets involved in cell motility, cellular differentiation and growth pathways in BL cells lacking nuclear isoform c expression. These results suggest that NERB-2 function modulates tumor growth and promotes a metastatic phenotype in TNBC. Furthermore, our clinical findings identified NERB-2 as an independent predictor of shorter OS

(HR 2.54; 95% CI 1.22-5.28;  $P = 0.013$ ), DFS (HR 2.91; 95% CI 1.44-5.87;  $P = 0.003$ ), and DMFS (HR 2.59; 95% CI 1.20-5.60;  $P = 0.015$ ) in 99 TN primary tumors. Our discoveries challenge the present scenario of drug development for personalized BC medicine that focuses on wild-type proteins, which conserve the canonical domains and are located in their classical cellular compartments, highlighting the potential of NERB-2 isoforms as novel therapeutic targets and clinical biomarkers in TNBC.

## Tumor Biology

### HORMONE ACTIONS IN TUMOR BIOLOGY: FROM NEW MECHANISMS TO THERAPY

#### *Osteoblast-Induced Prostate Cancer Cell Migration and Invasion Is Mediated Through TGF- $\beta$ 1/SMAD2 Signal Pathway and Blocked by 17 $\alpha$ -Estradiol*

Jian Shi, MD, Lian Zhao, MD, Brittany Duncan, BS, Jie Su, PhD, Jale Manzo, BS, He Liu, MD, Yuan-Shan Zhu, MD, PhD. Weill Cornell Medical College, New York, NY, USA.

Prostate cancer (PCa) is curable if it is diagnosed and treated in localized and regional stage. However, PCa outcome is poor once it has distant metastasis. Approximately 70% to 100% of PCa deaths have bone metastasis, which may be associated with a specific bone microenvironment. In this study, we investigated the effect and molecular mechanism of osteoblast cells on stimulation of PCa cell migration and invasion and examined the effectiveness of 17 $\alpha$ -estradiol on blocking osteoblast-induced PCa cell migration and invasion using *in vitro* cell analysis. PCa cells (PC3, LNCaP and DU145), osteoblast hFOB, kidney CV-1, breast tumor MCF-7 and liver cancer Huh-7 cells (ATCC) were cultured in RPMI-1640 or DMEM media supplemented with or without fetal bovine serum (FBS) at 37 °C in a 5% CO<sub>2</sub>-humidified incubator. hFOB condition media (HCM) without FBS were collected at different times of hFOB cell culture. Transwell and wound-healing experiments were used to determine PCa cell migration and invasion. Cell migration and invasion in PC3, DU-145 and LNCaP PCa cells were markedly promoted by co-culturing hFOB osteoblast cells or HCM, but not by cells or condition media originated from kidney (CV-1), liver (Huh-7) and breast (MCF-7). Compared to other non-osteoblast cell conditioned media, HCM had much higher levels of several cytokines and chemokines including tumor growth factor (TGF)  $\beta$ 1. Both HCM and TGF- $\beta$ 1 produced a dose- and time-dependent induction of PCa cell migration and invasion as well as SMAD2 phosphorylation without altering cell proliferation. These HCM and TGF- $\beta$ 1 effects were inhibited by a specific TGF $\beta$  receptor inhibitor, LY2157299, as well as by 17 $\alpha$ -estradiol in a dose-dependent manner. Most intriguing, 17 $\alpha$ -estradiol significantly inhibited the HCM and TGF- $\beta$ 1-induced PCa cell migration and invasion at very low nanomolar concentrations, presumably mediated

through estrogen receptor  $\beta$ . These findings suggest that TGF- $\beta$ 1 is a major factor in mediating hFOB cell stimulation of PCa cell migration and invasion, and 17 $\alpha$ -estradiol is a potential agent to block PCa cell bone metastasis, probably through inhibition of TGF- $\beta$ 1/SMAD2 signal pathway.

## Tumor Biology

### HORMONE ACTIONS IN TUMOR BIOLOGY: FROM NEW MECHANISMS TO THERAPY

#### *Preclinical Evidence of the Efficacy of Lewis Y Car T Cells in Patient-Derived Models of Prostate Cancer*

Gail Petuna Risbridger, PhD<sup>1</sup>, Laura Helen Porter, BSc(hons)<sup>1</sup>, Joe Zhu, PhD<sup>2</sup>, David Byrne, Nil<sup>2</sup>, Natalie Lister, PhD<sup>3</sup>, Arun Azad, MD, PhD<sup>2</sup>, Michael Hofman, MD<sup>2</sup>, Ian Vela, MD, PhD<sup>4</sup>, Melbourne Urological Research Alliance (MURAL), Nil<sup>1</sup>, Renea A. Taylor, PhD<sup>3</sup>, Paul Neeson, PhD<sup>2</sup>, Phil Darcy, PhD<sup>2</sup>, Joseph Trapani, MD, PhD<sup>2</sup>.

<sup>1</sup>Monash University, Clayton, Victoria, Australia, <sup>2</sup>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, <sup>3</sup>Monash University, Clayton, Australia, <sup>4</sup>Queensland University of Technology, Brisbane, Queensland, Australia.

Chimeric antigen receptor T (CAR T) cell therapy is an adoptive immunotherapy that has led to new treatments for lymphoma, leukemia, and other blood cancers; however, its efficacy for prostate cancer remains unproven. Here we report pre-clinical evidence of the efficacy of CAR T cell therapy against the Lewis Y antigen (LeY) using patient-derived models of prostate cancer. To assess the expression of LeY on prostate tumours, we performed immunohistochemistry on a cohort of 41 patient-derived xenografts (PDXs). Cytoplasmic and membrane expression were separately assessed and quantified, for each patient. Overall, 61% (25/41) of PDXs were positive for membrane LeY expression, of which 18 PDXs had greater than 50% membrane-positive cells, and considered most suitable to detection and stable binding by anti-LeY CAR T's. To determine the *in vitro* sensitivity to CAR T cytotoxicity, we selected 4 PDXs with high and 2 PDXs with low LeY expression using 3 androgen receptor (AR)-positive adenocarcinomas and 3 AR-negative tumors expressing neuroendocrine markers. Next we established organoids for *in vitro* co-culture assays where organoids were co-incubated with an equal number of anti-LeY+ CAR T cells or Empty vector control CAR T cells (Ev CAR T). Using time-lapse microscopy we reported destruction of organoids by LeY+ CAR T cells as indicated by their morphological collapse and uptake of propidium iodide from the culture medium; control Ev CAR T cells produced no cytotoxicity. Over the 48h assay, the level of target cell death of the LeY+ organoids was correlated to the intensity LeY surface expression. Target cell death mediated by the CAR T cells required perforin and granzyme B, as potent and highly specific small molecule inhibitors of perforin (SN34960) and granzyme B (C20) applied alone or in combination greatly decreased PI uptake, indicating organoid survival. Neither inhibitor adversely affected CAR T cell viability as measured by PI and Annexin V staining. This demonstrated canonical activation of granule exocytosis pathway by the CAR T cells, leading to organoid cell death. To assess CAR T cell efficacy *in vivo*, we selected one PDX